Physician profile
Nathan Petula
NPI 1245363365
$15,510.59
in general payments reported to CMS, 2019-2025
44 companies · $3,109 in 2025
The $3,109 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $6.00 · 2021: $3,102 · 2022: $3,102 · 2023: $2,999 · 2024: $3,193 · 2025: $3,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,195 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,194.87 |
| Education | $105.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,347.35 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Teva Pharmaceuticals USA, INC. | $2,529.13 | 2021-2025 | Austedo Xr, Austedo, Uzedy |
| Abbvie INC. | $1,486.85 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,283.27 | 2021-2025 | Farxiga, Fasenra, Airsupra |
| Lilly USA, LLC | $1,064.54 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $564.16 | 2021-2025 | |
| Glaxosmithkline, LLC. | $550.03 | 2021-2025 | Trelegy Ellipta, Pediarix, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $499.66 | 2021-2025 | |
| Amgen INC. | $391.67 | 2021-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $298.79 | 2021-2025 | Gardasil 9, Vaxelis, M-M-R II |
| Otsuka America Pharmaceutical, INC. | $287.77 | 2021-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $264.00 | 2021-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.88 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $236.39 | 2021-2024 | Xarelto, Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $228.57 | 2021-2025 | Trintellix |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $184.67 | 2021-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $171.43 | 2024-2025 | Voquezna |
| Sanofi Pasteur INC. | $160.54 | 2022-2023 | |
| Abbott Laboratories | $140.51 | 2022-2025 | Freestyle Libre, Freestyle Libre 3 |
| Daiichi Sankyo INC. | $136.14 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $131.33 | 2021-2025 | |
| Exact Sciences Corporation | $124.25 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $121.63 | 2022-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $118.25 | 2021 | |
| Axsome Therapeutics, INC. | $116.18 | 2024-2025 | Auvelity |
| Astellas Pharma US INC | $116.05 | 2023-2025 | Veozah, Myrbetriq |
| Cequr Corporation | $93.04 | 2025 | Cequr Simplicity |
| Baxter Healthcare | $86.15 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Sanofi-Aventis U.S. LLC | $78.89 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $62.99 | 2022 | |
| Biogen, INC. | $58.15 | 2021 | |
| Lundbeck LLC | $42.63 | 2024 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $41.59 | 2021 | |
| Ucb, INC. | $40.05 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $33.36 | 2021 | |
| Organon LLC | $27.70 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $27.56 | 2025 | Purified Cortrophin Gel |
| Alnylam Pharmaceuticals INC. | $18.11 | 2023 | Onpattro |
| Ibsa Pharma INC. | $16.84 | 2021 | |
| Acadia Pharmaceuticals INC | $16.11 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.04 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $15.52 | 2025 | Gvoke Hypopen |
| Acella Pharmaceuticals, LLC | $13.82 | 2025 | NP Thyroid 60 |
| Bardy Diagnostics, INC. | $6.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Petula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.